Core Insights - Agereh Technologies Inc. is positioned for accelerated commercial growth with a strong Board of Directors and executive leadership team as it transitions into its commercial growth phase [1][2] Leadership and Governance - The governance structure of Agereh combines expertise in technology commercialization, public markets, finance, and large-scale enterprise operations, which is crucial for the company's growth [2] - Ken Brizel, CEO and Director, emphasizes the importance of experienced leadership to guide growth and ensure disciplined governance [3] - The Board of Directors includes individuals with extensive backgrounds in technology and finance, such as Jim Plumptre, Mike Plotnikoff, Tim Maddigan, and Rosy Amlani, each bringing over 20 years of experience in their respective fields [4][5][6][7] Executive Management - Ken Brizel leads the strategic direction and product commercialization efforts of Agereh [8] - Joanna L. Hampton, as Chief Financial Officer, oversees financial operations and regulatory reporting, focusing on disciplined governance [9][10] Strategic Growth Initiatives - Agereh's leadership team is focused on expanding its unified intelligent sensing platform across transportation hubs, supporting scalable growth and long-term strategic partnerships [11] - The company aims to build recurring SaaS revenue and enhance its presence in intelligent transportation systems [12] Company Overview - Agereh Technologies Inc. specializes in AI-enabled platforms and sensor solutions aimed at addressing challenges in the transportation industry, enhancing efficiency and optimizing operations [13]

~ Delivered 8% sales growth and 21% adjusted EPS growth in full year 2025 ~ ~ 2026 Outlook maintains midpoint of sales growth and high end of adjusted EPS growth from October outlook ~~ Continue to expect 200bps above-market organic sales growth in 2027 ~ PLANO, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading contract development and manufacturing organization, today announced results for the three and twelve months ended December 31, 2025. Unless otherwise state ...

Core Viewpoint - Virtuix Inc. is celebrating its listing on the Nasdaq by ringing the closing bell on March 4, 2026, marking a significant milestone for the company and its shareholders [2][7]. Group 1: Company Announcement - The Nasdaq closing bell ceremony will be broadcast live, starting at 3:45 p.m. Eastern Time, with the bell ringing at 4:00 p.m. Eastern Time [3]. - Company management will be in New York City from March 2 to 6, 2026, for media interviews and investor meetings [4]. Group 2: Company Overview - Virtuix Inc. is a leading manufacturer of full-body virtual reality systems, targeting consumer, enterprise, and defense markets [5]. - The company's flagship product, the "Omni" omni-directional treadmill, allows users to walk and run in 360 degrees within virtual reality applications [5]. - Virtuix is committed to innovation in XR and AI, aiming to deliver immersive experiences globally [5].

Core Insights - NorthStrive Biosciences, Inc. has filed ten new U.S. patent applications to expand its proprietary EL-22 and EL-32 technologies into animal health and agricultural markets, focusing on muscle growth and weight return in animals [1][2]. Group 1: Patent Applications Overview - The ten patent applications consist of five covering EL-22 and five covering EL-32, applicable across various farmed animal categories including livestock, aquaculture, and poultry [2]. - Two applications specifically address the use of EL-22 and EL-32 as non-feed additive supplements to promote muscle tissue growth and increase muscle weight return per animal [3]. Group 2: Environmental and Health Benefits - Additional applications aim to utilize EL-22 and EL-32 for reducing gaseous emissions in livestock, which could lower environmental impact and mitigate risks associated with ruminal tympany [4]. - In aquaculture, applications have been filed to promote muscle growth in aquatic species, potentially reducing the time to reach commercially viable sizes and lowering energy costs [5]. - Further aquaculture applications focus on emissions reduction to help mitigate eutrophic conditions [6]. Group 3: Poultry Applications - The final set of applications pertains to the use of EL-22 and EL-32 in poultry, aimed at enhancing muscle growth and improving muscle yield per bird within standard growth timelines [7]. Company Background - NorthStrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., concentrating on developing advanced aesthetic medicines, with its lead asset, EL-22, designed to address muscle preservation during weight loss treatments [8].

Core Viewpoint - Intellia Therapeutics, Inc. is set to host a conference call on February 26, 2026, to discuss its fourth quarter and full-year 2025 financial results and business updates [1]. Group 1: Company Overview - Intellia Therapeutics is a leading clinical-stage gene editing company focused on CRISPR-based therapies aimed at revolutionizing medicine [3]. - The company aims to develop novel, first-in-class medicines that address significant unmet medical needs and advance treatment paradigms for patients [3]. - Intellia is expanding its CRISPR-based platform with novel editing and delivery technologies to harness the full potential of gene editing [3]. Group 2: Conference Call Details - The conference call will take place at 8 a.m. ET on February 26, 2026 [1]. - U.S. callers can join the teleconference by dialing 1-833-316-0545, while international callers should dial 1-412-317-5726 [2]. - A replay of the call will be available for approximately 90 days on the Events page of Intellia's website [2].

Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S. Food and Drug Administration (FDA) Pre-launch activities for ulixacaltamide and relutrigine are underway and will accelerate through 2026 Essential3 results to be presented as an oral presentation at the American Academy of Neurology Annual Meeting Cash and investments of $926 million as of December 31, 2025 and ...

Core Insights - DT Midstream, Inc. reported a strong financial performance for the fourth quarter and full year of 2025, achieving record results with a 17% year-over-year growth in Adjusted EBITDA [3][7]. Financial Performance - Fourth quarter 2025 reported net income was $111 million, or $1.08 per diluted share, with Operating Earnings also at $111 million [1]. - Full year 2025 reported net income was $441 million, or $4.30 per diluted share, with Operating Earnings matching this figure [2]. - Adjusted EBITDA for the fourth quarter was $293 million, while for the full year it reached $1.138 billion, reflecting a 17% increase from 2024 [2][7]. Business Strategy and Growth - The company successfully integrated its Midwest pipelines and completed key organic growth projects ahead of schedule and on budget, positioning itself to meet increasing demand [3]. - The organic project backlog increased by approximately 50% to $3.4 billion over the next five years, with pipeline projects making up 75% of this backlog [8]. - Adjusted EBITDA guidance for 2026 is projected to be between $1.155 billion and $1.225 billion, indicating a 6% annual growth from the original 2025 guidance [4]. Dividend and Investment Decisions - The company announced a 7% increase in dividends from the fourth quarter of 2025 to $0.88 per share, payable on April 15, 2026 [8]. - Final investment decisions were reached on two pipeline projects, including an expansion of Viking Gas Transmission [7][8].

Core Viewpoint - BrainsWay has entered into a strategic equity financing agreement with BrainStim Health Inc. to enhance access to mental health care through investments in innovative clinical service platforms [1][2] Group 1: Investment Details - BrainsWay will initially invest $1.0 million in BrainStim, with the potential for an additional $1.5 million based on milestones, acquiring a minority position through preferred, annually compounding securities [1] - This investment marks BrainsWay's fifth minority-stake investment in growth-oriented clinical service platforms, aligning with its strategic initiative to expand access to advanced mental health interventions [2] Group 2: Company Background - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) technology [4] - The company has received FDA clearance for three indications: major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and is committed to advancing its clinical applications [4] Group 3: BrainStim Overview - BrainStim focuses on delivering effective mental health protocols for conditions such as severe trauma, stress, anxiety, and depression, particularly for veterans and first responders [5] - The practice employs a team of board-certified psychiatrists and advanced psychiatric nurse practitioners to provide cutting-edge treatment options [5]

On 19 February 2026, AB Akola Group held an investor webinar, where the company's Deputy CEO for Finance and Investments Mažvydas Šileika presented the financial results for the 6 months of the 2025/2026 financial year. The recording of the webinar is available on Nasdaq’s YouTube account: https://youtu.be/vr1pFEOkIHQ?si=uWHqxS-VYYVNI5YB Link to the presentation demonstrated at the webinar: https://www.akolagroup.lt/wp-content/uploads/2026/02/260219_AKOLA_6M_webinar_M.Sileika_final-1.pdf For more informatio ...

VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- One Bullion Ltd. (“One Bullion” or the “Company”) (TSXV: OBUL), a gold exploration company holding complete ownership of three highly prospective mining areas in Botswana, today announced that management will host a booth at PDAC 2026, The World’s Premier Mineral Exploration & Mining Convention, taking place March 1-4, 2026, in Toronto, Canada. PDAC 2026 Booth Details:Date: March 3-4, 2026Location: Metro Toronto Convention Centre, Toronto, Ontar ...